Research News on Chemotherapy
-
HER2 and Topo II Status Affects Response to Anthracycline Chemo
A new study suggests that anthracycline-based chemotherapy regimens should be used to treat only HER2-positive breast cancers.
-
Scientists Report on New Breast Cancer Treatments
A number of studies are looking at new ways to treat breast cancer, including testing the effectiveness of new compounds and new uses for current medicines.
-
Zometa Seems to Improve Response to Chemotherapy
Research suggests that Zometa, a medicine used to strengthen bones, may slow breast cancer growth.
-
New Chemo Meds Improve Survival for Women with Advanced-Stage Disease
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
-
Xeloda and Avastin Combo Better Than Xeloda Alone for Metastatic Disease
The combination of Xeloda (chemical name: capecitabine) and Avastin (chemical name: bevacizumab) has been shown to stop metastatic breast cancer from growing longer than Xeloda alone.
-
Cancers Resistant to Anthracyclines May Respond to Taxotere-Xeloda Combo
A new study suggests that breast cancer that is resistant to an anthracycline may respond to a combination of two other chemotherapies, Taxotere (chemical name: docetaxel) and Xeloda (chemical name: capecitabine).
-
Zometa During and After Chemo Helps Keep Bones Strong
A small study shows that Zometa (chemical name: zoledronic acid) given during and after chemotherapy for early-stage breast cancer maintained bone health in pre-menopausal women.
-
Actonel Boosts Bone Health After Chemo
Actonel (chemical name: risendronate), a bone-strengthening medicine, can improve bone health after chemotherapy for breast cancer. Actonel can also lessen the bone weakening that sometimes happens when hormonal therapy is used after chemotherapy.
-
Evista Reduces Risk of Hormone-Receptor-Positive Cancers in Postmenopausal Women
Results of the RUTH (Raloxifene Use for The Heart) study reinforce earlier research showing that Evista (chemical name: raloxifene) can reduce breast cancer risk in post-menopausal women.
-
Metformin Seems to Enhance Power of Chemotherapy
Women who were taking the medicine metformin to treat diabetes were more likely to respond to breast cancer chemotherapy before surgery than diabetic women not taking metformin.
